Form 4: Indaptus Therapeutics Director William B. Hayes Acquires Stock Options
SEC Form 4
Director William B. Hayes acquired 12,500 stock options in Indaptus Therapeutics on June 6, 2024.
Summary
- On June 6, 2024, William B. Hayes, a director of Indaptus Therapeutics, Inc., acquired 12,500 stock options.
- The options have an exercise price of $2.63.
- The stock options vest and become exercisable on June 6, 2025.
- The options expire on June 6, 2034.
- Following the transaction, Hayes directly owns 12,500 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure of stock option grants to a company director, which is a common practice in publicly traded companies to align management's interests with those of shareholders.
Stakeholder Impact
- The granting of stock options to a director can align their interests with those of shareholders, potentially incentivizing them to increase company value.
Key Dates
| Date | Description |
|---|---|
| 06/06/2024 | Date of transaction: William B. Hayes acquired stock options. |
| 06/06/2025 | Stock options vest and become exercisable. |
| 06/06/2034 | Expiration date of the stock options. |
| 06/07/2024 | Date of signature on the Form 4. |
Keywords
stock options, Form 4, Indaptus Therapeutics, director, beneficial ownership, INDP, Hayes
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.